Literature DB >> 8124911

Soluble CD4 and CD8 molecules in patients with systemic sclerosis.

Y Tokano1, H Kaneko, T Obara, H Hashimoto, K Okumura, S Hirose.   

Abstract

The concentrations of sCD4 and sCD8 in 69 patients with systemic sclerosis (SSc) were examined by using a sandwich enzyme-linked immunosorbent assay. The patients with SSc had significantly higher concentrations of sCD8 (mean 249.2 U/ml (SD 155.1), median 224 U/ml) than the normal subjects (mean 149.3 U/ml (SD 42.1), median 148 U/ml). The concentration of sCD4 in patients with SSc were significantly lower (mean 6.2 U/ml (SD 3.8), median 5.0 U/ml) than in the normal subjects (mean 10.9 U/ml (SD 4.1), median 10.3 U/ml). The concentration of sCD8 in patients with diffuse sclerosis tended to be higher than in those with sclerodactyly.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8124911     DOI: 10.1007/bf02231777

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  12 in total

1.  High serum levels of CD8 antigen in primary biliary cirrhosis: a possible cause of suppressor cell dysfunction?

Authors:  K T Nouri Aria; M Lombard; R Williams
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

2.  Serum soluble CD4 and CD8 levels in Kawasaki disease.

Authors:  S Furukawa; T Matsubara; K Tsuji; T Motohashi; K Okumura; K Yabuta
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

3.  Soluble CD8 during T cell activation.

Authors:  B E Tomkinson; M C Brown; S H Ip; S Carrabis; J L Sullivan
Journal:  J Immunol       Date:  1989-04-01       Impact factor: 5.422

4.  Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations.

Authors:  D Degiannis; J R Seibold; M Czarnecki; J Raskova; K Raska
Journal:  Arthritis Rheum       Date:  1990-03

5.  Soluble CD8 in patients with rheumatic diseases.

Authors:  J A Symons; N C Wood; F S di Giovine; G W Duff
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

6.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

7.  Increased soluble CD4 and decreased soluble CD8 molecules in patients with Sjögren's syndrome.

Authors:  S Sawada; S Sugai; S Iijima; M Takei; E Paredes; T Hayama; S Nishinarita; Y Hosokawa; T Horie; T Obara
Journal:  Am J Med       Date:  1992-02       Impact factor: 4.965

8.  Phenotype of peripheral blood lymphocytes in patients with progressive systemic sclerosis: activated T lymphocytes and the effect of D-penicillamine therapy.

Authors:  B Freundlich; S A Jimenez
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

9.  Immunoregulatory T cell subpopulations in patients with scleroderma using monoclonal antibodies.

Authors:  E C Keystone; C Lau; D D Gladman; S Wilkinson; P Lee; A Shore
Journal:  Clin Exp Immunol       Date:  1982-05       Impact factor: 4.330

10.  Serum levels of CD8 antigen in childhood lymphoid malignancies: a possible indicator of increased suppressor cell activity in poor-risk patients.

Authors:  C H Pui; S H Ip; R K Dodge; S Carrabis; M Brown; W M Crist; C W Berard; P Kung; G V Dahl; S B Murphy
Journal:  Blood       Date:  1988-09       Impact factor: 22.113

View more
  1 in total

1.  Soluble CD4 and CD8 in serum from patients with localized scleroderma.

Authors:  S Sato; M Fujimoto; K Kikuchi; H Ihn; K Tamaki; K Takehara
Journal:  Arch Dermatol Res       Date:  1996-06       Impact factor: 3.017

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.